April 2026 psychedelic research highlighted clinical trials in cancer, depression, suicidality, OCD and BPD, alongside mechanistic, methodological and review papers on psychedelics, ketamine, esketamine and MDMA.
April’s papers were dominated by human studies that stayed close to care: trials and real-world cohorts in cancer, depression, suicidality, obsessive-compulsive disorder and borderline personality disorder.
Alongside them were studies of blinding, placebo effects, brain connectivity, mystical experience, and long-term psychedelic use, plus a smaller set of preclinical papers that helped sharpen the mechanistic picture.
Taken together, the month showed a field that is moving between practical questions about who benefits, how to deliver treatment safely, and how to separate drug effects from context and expectation.
This section covers patient-facing studies closest to care. The strongest direct clinical signals come first, followed by smaller case series, protocol work, facilitator training, and trial-specific support papers. The shared question is what these treatments might look like when tested or delivered in real clinical populations.
In an open-label pilot study of adults with borderline personality disorder and major depressive disorder, a single dose of psilocybin was linked with a clear reduction in depressive symptoms over four weeks, but borderline personality disorder symptoms did not change significantly. The small sample means the finding is best read as an early signal that BPD did not prevent antidepressant benefit, rather than proof that psilocybin treats BPD itself.
In a pilot randomised trial of adolescents in the emergency department, single-dose IV ketamine was feasible, well tolerated, and produced no clear overall advantage on suicidal ideation at 40 minutes, although a suicidal ideation questionnaire (SSI5) suggested a possible early reduction and fewer ketamine-treated participants were admitted at the index visit. The study supports the practicality of emergency department research in young people, but the clinical signal remains tentative.
In advanced cancer, secondary analyses of the INKeD-PC trial suggested that intranasal racemic ketamine may do more than lift mood. Depression, anxiety, death and dying distress, quality of life and overall symptom burden all improved, with psychological changes appearing more prominent than physical ones. The paper presents this as preliminary but encouraging evidence for a broader palliative care role.
A multicentre prospective observational study of intranasal esketamine in treatment-resistant depression found sustained reductions in suicidal ideation, suicidal behaviour and deliberate self-harm over six months, including in people with comorbid borderline personality disorder. The pattern was clinically reassuring because no increase in suicidality emerged, but the authors rightly note that the design cannot separate esketamine from the wider care pathway.
In a small prospective case series, repeated intranasal esketamine augmentation was associated with improvement in both obsessive-compulsive and depressive symptoms in people with treatment-resistant OCD and comorbid major depressive disorder. Depression improved earlier and more consistently than OCD, which is a useful reminder that different symptom domains may move on different timelines.
A facilitator-training analysis from a psilocybin depression trial evaluated a 15-week programme for nurses supporting treatment sessions. Some role-play communication skills improved, but the gains were modest and most facilitators still wanted more practical in-person preparation.
A ketamine-under-propofol protocol and pilot is testing whether ketamine can help chronic pain with depression, while propofol sedation improves blinding. Among the first six pilot participants, there were no serious adverse events, although many could still guess their allocation shortly after sedation.
These papers focus on depression, suicidality, retreatment, and longer-term esketamine or ketamine use. They are clinically relevant, but many rely on observational designs, small samples, or selected follow-up cohorts.
In metastatic cancer, a Phase I follow-up study tested a second group retreat psilocybin therapy session for partial responders to the earlier retreat trial. The intervention was well tolerated, with no serious adverse events, and anxiety and depression scores improved further after the second experience, alongside a marked rise in complete mystical experience. The paper makes a careful case for retreatment and more flexible dosing, while also showing how access and scalability remain central issues.
A naturalistic study of intravenous ketamine in treatment-resistant depression suggested that both bipolar and unipolar depression improve, but bipolar depression may respond faster and more strongly. Dissociation stayed broadly stable, and sex did not clearly shape antidepressant response, though there were some sex-linked differences in dissociation. It is a useful real-world signal, but one that still needs controlled confirmation.
A five-year observational cohort described long-term dosing patterns and symptom trajectories with adjunctive intranasal esketamine in treatment-resistant depression. Among people who stayed on treatment, depressive symptoms fell substantially and remained low over time, with no hypomania or mania reported. The study is descriptive, but it gives a practical view of how esketamine is being used outside trials.
A small open-label Phase II trial in treatment-resistant depression found that higher baseline interleukin-6 was linked to faster symptom reduction during intranasal esketamine treatment, while IL-6 itself did not fall over time. Depression and disability improved, which makes IL-6 an interesting candidate biomarker, though the authors are clear that the study is only hypothesis-generating (also see this great analysis on IL-6 from Adam Borecky).
A case report described ketamine addiction developing after a single sub-anaesthetic intranasal dose given for acute suicidality. The patient later escalated to daily illicit ketamine use, then polysubstance misuse, and eventually attempted suicide when access stopped. It is a stark reminder that even a single therapeutic exposure may matter in vulnerable individuals.
This section shifts from symptoms to experiences, support, and aftermath. It includes work on mystical experiences, extended difficulties, challenging experiences, and therapist perspectives. The common thread is that psychedelic outcomes depend not only on the drug, but on meaning, context, preparation, and integration.
In a real-world observational study of esketamine for treatment-resistant depression, mystical-type experiences were common and varied across sessions, and stronger mystical intensity, especially positive mood, was associated with greater antidepressant improvement. Dissociation did not explain the clinical change nearly as well, which is a useful corrective to the idea that the acute experience is just a side effect.
A global, multilingual survey found that nearly half of respondents reported extended difficulties after psychedelic use, and about 8% described problems that were both long lasting and disruptive to daily life. Existential struggle, depression and derealisation were the most common themes, and the study makes clear that difficult aftermaths can be substantial even when many people still view their experiences positively.
A naturalistic survey study examined post-traumatic stress symptoms following particularly challenging psychedelic experiences and found that about a third of the selected sample met self-reported PTSD criteria afterwards. Acceptance during the acute experience was linked with lower PTSD severity and more post-traumatic growth, while avoidance predicted worse outcomes. The paper is careful to avoid overgeneralising, but it underlines that some difficult psychedelic experiences can be genuinely traumatic.
A qualitative interview study of Swiss therapists practising psychedelic-assisted therapy found a strongly synergistic view of psychotherapy and the drug experience. Therapists described preparation, a safe setting and integration as central, and most saw psychedelics as catalysts for psychotherapy rather than replacements for it.
These papers step back to ask how the evidence should be interpreted. They cover depression meta-analysis, blinding, placebo effects, implementation, memory claims, and broader clinical framing. They are important because methodology often shapes the size and meaning of psychedelic trial effects.
An international mega-analysis of resting-state MRI data found a common acute psychedelic signature across psilocybin, LSD, mescaline, DMT and ayahuasca: increased connectivity between higher-order and sensory networks, with mixed and more modest reductions within networks. The work gives the field a more stable network-level map than single-site studies have managed so far.
A living systematic review and meta-analysis of randomised psilocybin trials found that psilocybin-assisted therapy reduces depression scores more than control conditions overall. The evidence base is still small and uneven, but the direction of travel is consistent.
A systematic review of blinding integrity in psychedelic randomised trials found that only about a third of studies assessed blinding formally, while functional unblinding was common, especially in psilocybin, LSD, ayahuasca and MDMA studies. The review does not offer a perfect fix, but it makes a strong case that expectancy must be measured rather than assumed away.
A broader review of placebo effects in psychiatry placed psychedelic trials in the context of larger questions about expectancy, blinding and outcome interpretation. It argues that placebo is not a nuisance variable to be ignored, but a central part of how psychiatric trials work, especially where subjective outcomes dominate.
A scoping review of repressed-memory claims in psychedelic contexts found no coherent empirical basis for the idea that psychedelics reliably recover repressed memories. The authors do, however, urge clinicians to treat such reports carefully and with empathy, rather than dismissing them outright.
A narrative review of psychedelics in borderline personality disorder concluded that ketamine and esketamine have the most promising early signal, with psilocybin far less developed. Safety remains a major concern, but the paper suggests BPD should not automatically exclude people from future psychedelic research.
A narrative review of clinical MDMA doses in healthy volunteers found a fairly consistent profile of acute empathy, trust and emotional openness, alongside temporary memory impairment and some psychomotor slowing. For psychotherapy, the appeal is obvious, but the same profile also creates blinding and safety challenges that trials still need to handle better.
This final mechanism section covers connectivity, anaesthesia, synapses, interneurons, and new analogues rather than direct patient outcomes. These papers help build biological explanations for psychedelic and ketamine effects. Most sit further from clinical practice than the human studies above.
In methamphetamine use disorder, psilocybin-assisted psychotherapy was associated with reorganisation of both large-scale and local functional connectivity, including shifts in attention, default mode, salience and frontoparietal networks. The study is exploratory, but it points to a plausible neural pathway through which treatment may relate to reductions in use and distress.
A cohort study on ketamine neurophysiology under general anaesthesia suggested that some of ketamine’s brain activity patterns persist while others are altered, separating beta-gamma effects from the usual theta increase. It is a niche paper, but useful for thinking about which neurophysiological features are tied to state and which may be more specific to ketamine.
In rodents, psilocybin increased the formation and maturation of new synapses while speeding the loss of older ones, and these neuroplastic effects were separated from hallucinogen-like behaviour. The paper is a brief preprint, but it neatly reinforces the growing view that plasticity and subjective effects can be teased apart.
Another preclinical preprint suggests psilocybin reshapes cortical inhibition by suppressing somatostatin interneurons and recruiting parvalbumin interneurons in the medial frontal cortex. The work is still early, but it points to a more detailed cell-type account of how psilocybin may alter cortical dynamics.
Another preclinical study of R-MDDMA, a structural analogue of MDMA, suggested that the compound may preserve some psychoplastogenic and antidepressant-like actions while avoiding several of MDMA’s liabilities. It is an early medicinal chemistry result, but it fits neatly with the month’s broader interest in separating therapeutic from unwanted effects.
This final section covers the remaining papers on mostly healthy-volunteer, naturalistic, observational, or early pharmacology studies that warrant shorter notes. They still add texture to the month, but they should not be weighted as heavily as the patient studies and reviews above.
A double-blind crossover study compared acute 2C-B, MDMA and psilocybin effects in healthy adults. Higher-dose 2C-B looked partly MDMA-like and partly psychedelic-like, while MDMA produced the strongest cardiovascular stimulation, and psilocybin produced more anxiety and unpleasant effects.
A preregistered cross-sectional fMRI study compared experienced naturalistic psychedelic users with matched non-users during an emotional face task. Users were faster and more accurate at recognising angry faces and showed altered limbic, salience, parietal and sensorimotor responses, though the design cannot show whether psychedelic use caused those differences.
A retrospective survey of people using psychedelics naturalistically tested a questionnaire on major life changes after psychedelic use. Most respondents reported at least one major change, especially in goals, values or spirituality, but the self-selected design means the high rates should be read cautiously.
An observational ayahuasca study linked subjective effects with changes in blood alkaloids, metabolism and brain network connectivity in experienced users. It is a small brain-body mapping study rather than a clinical trial, but it broadens the kinds of signals measured during psychedelic experiences.
A mouse study of 2-halogenated tryptamines found that DMT and psilocybin derivatives had lower activity at receptors tied to psychedelic effects and possible heart risks while keeping strong 5-HT6 activity. This is early pharmacology work, useful mainly for thinking about future compound design.
Paper Records
All papers from this recap month